Dr. R. Nicoletti and Prof. E. Compérat present the case against renaming Gleason score 6 in prostate cancer

They discuss the strong pathological arguments for keeping the "cancer" designation, pointing to the morphological and molecular evidence that supports this classification. Prof. Comperat highlights the risks of causing confusion within the clinical and research communities if Gleason score 6 were no longer considered cancer.

The episode also addresses the potential impact on prostate cancer reporting and the broader implications for treatment decision-making. This discussion presents a compelling counterpoint to the proposal of renaming Gleason score 6, emphasising the importance of consistency in cancer classification.

For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.